erythromycin has been researched along with cefetamet in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (42.86) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Bale, MJ; Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Washington, JA | 1 |
Black, WA; Bowie, WR; Chan, DG; Shaw, CE | 1 |
Brunham, RC; Le Saux, NM; Plummer, FA; Ronald, AR; Slaney, LA | 1 |
Jalanko, E; Renkonen, OV; Scheinin, L; Valle, T | 1 |
7 other study(ies) available for erythromycin and cefetamet
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.
Topics: Anti-Bacterial Agents; Cefdinir; Cefpirome; Ceftibuten; Ceftizoxime; Cephalosporins; Clarithromycin; Erythromycin; Fleroxacin; Fluoroquinolones; Haemophilus; Humans; Microbial Sensitivity Tests; Quality Control; Quinolones; Spectinomycin; Virginiamycin | 1992 |
In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis.
Topics: Anti-Bacterial Agents; Cefmenoxime; Ceftizoxime; Cephalosporins; Chlamydia trachomatis; Clarithromycin; Erythromycin; Leucomycins; Microbial Sensitivity Tests; Neisseria gonorrhoeae | 1987 |
In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.
Topics: Cefmenoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Erythromycin; Fleroxacin; Haemophilus ducreyi; Humans; Neisseria gonorrhoeae; Penicillins; Spectinomycin; Tetracycline | 1987 |
In vitro activity of RO 15-8074 and RO 19-5247.
Topics: Amoxicillin; Bacteria; Cefmenoxime; Ceftizoxime; Cephalosporins; Enterobacteriaceae; Erythromycin; Haemophilus influenzae; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Staphylococcus; Streptococcus | 1987 |